Heron Therapeutics Announces Third Quarter 2026 Financial Results

(NASDAQ:HRTX) Heron Therapeutics, Inc. announced financial results for the three and nine months ended September 30, 2026, and provided recent corporate updates. Total net revenue for Q3 2026 was $35.3 million, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. The company ended the third quarter with $23.4 million in cash, cash equivalents, and short-term investments. Acute Care franchise net revenue increased 22.5% year-over-year for Q3 2026 and 32.4% year-over-year for the nine months ended September 30, 2026. ZYNRELEF contributed $10.6 million and $31.9 million in net revenue for the three and nine months ended September 30, 2026, respectively. APONVIE contributed $4.5 million and $12.2 million in net revenue for the three and nine months ended September 30, 2026, respectively. Oncology Supportive Care franchise net revenue was $20.1 million in Q3 2026 and $63.5 million for the nine months ended September 30, 2026. CINVANTI contributed $20.0 million and $62.3 million in net revenue for the three and nine months ended September 30, 2026, respectively. Commercial sales of SUSTOL ceased on September 30, 2026. Heron and CorMedix Therapeutics entered into a definitive asset purchase agreement for CorMedix to acquire substantially all of Heron's assets, subject to Heron stockholder approval and customary closing conditions. The company withdrew its full-year 2026 financial guidance in August 2026 and is not providing guidance at this time. For Q3 2026, Acute Care net revenue was $15,128,000, APONVIE $4,530,000, ZYNRELEF $10,598,000, Oncology $20,122,000, CINVANTI $19,970,000, SUSTOL $152,000, and total net revenue $35,250,000. For the nine months ended September 30, 2026, Acute Care net revenue was $44,088,000, APONVIE $12,200,000, ZYNRELEF $31,888,000, Oncology $63,539,000, CINVANTI $62,298,000, SUSTOL $1,241,000, and total net revenue $107,627,000. Cost of product sales for Q3 2026 was $8,958,000 and for the nine months ended September 30, 2026 was $31,168,000. Gross profit for Q3 2026 was $26,292,000 and for the nine months ended September 30, 2026 was $76,459,000. Operating expenses for Q3 2026 were $27,961,000 and for the nine months ended September 30, 2026 were $84,937,000. Loss from operations was $1,669,000 for Q3 2026 and $8,478,000 for the nine months ended September 30, 2026. Net loss was $5,006,000 for Q3 2026 and $18,606,000 for the nine months ended September 30, 2026. Comprehensive loss was $5,007,000 for Q3 2026 and $18,617,000 for the nine months ended September 30, 2026. Basic net loss per share was $0.03 for Q3 2026 and $0.10 for the nine months ended September 30, 2026. Heron will not host a conference call or webcast for its third quarter 2026 financial results.

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics, Inc. (NASDAQ:HRTX) reported Q1 2026 total net revenue of $34.7 million, with its Acute Care franchise growing net revenue by 32% year-over-year, including ZYNRELEF (+27%) and APONVIE (+50%). The company reaffirmed its 2026 full-year guidance of $173–$183 million in net revenue and $10–$20 million in Adjusted EBITDA. Heron ended Q1 2026 with $44.8 million in cash, cash equivalents, and short-term investments. The company reached a settlement with Baxter Healthcare Corporation in CINVANTI patent litigation and highlighted ongoing commercial expansion and product updates. These results and updates are significant for investors as they demonstrate strong product growth, financial stability, and resolution of legal uncertainties.